search
Back to results

Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow (MelO2)

Primary Purpose

Vasospastic Syndrome

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Melatonin
Placebo
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Vasospastic Syndrome focused on measuring melatonin, skin blood flow, choroidal blood flow, vasospastic subjects, normal subjects

Eligibility Criteria

20 Years - 30 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • vasospastic syndrome
  • healthy

Exclusion Criteria:

  • sick
  • BMI >25 or <18
  • migraine
  • drug intake

Sites / Locations

  • University Eye Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

A, 1

A, 2

Arm Description

A, 1 = Melatonin

A,2 = Placebo

Outcomes

Primary Outcome Measures

-choroidal blood flow -oxygen consumption -Co2 production -skin temperatures -rectal temperatures -blood pressure -eye tension

Secondary Outcome Measures

Full Information

First Posted
May 6, 2008
Last Updated
September 10, 2012
Sponsor
University Hospital, Basel, Switzerland
search

1. Study Identification

Unique Protocol Identification Number
NCT00675181
Brief Title
Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow
Acronym
MelO2
Official Title
Effects of Melatonin on Oxygen Consumption and Choroidal Blood Flow in Women With Vasospastic Syndrome in Comparison to Controls
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
May 2008 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
January 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Does melatonin affect basal metabolic rate, increase choroidal blood flow and reduce the vasospastic syndrome (VS)? The main questions are: Do women with VS exhibit... a different basal metabolic rate a reduced choroidal blood flow a reduced increase of oxygen consumption after intake of ice-water a different oxygen consumption after melatonin intake a different choroidal blood flow after melatonin intake a different oxygen consumption after melatonin intake and after intake of ice-water….?
Detailed Description
Study description: Melatonin, a natural hormone of the pineal gland exclusively released during the dark phase, exhibits vasodilatatory effects in distal skin regions and reduces core body temperature. This study investigates whether exogenous melatonin (5mg p.o. at 2p.m.) in the afternoon, when no endogenous melatonin is secreted, increases not only distal skin blood flow, but also choroidal blood flow and changes oxygen consumption. Two subject groups were studied, women with vasospastic syndrome (VS) and controls. The main hypothesis is: melatonin normalizes distal vasoconstriction in VS. Further questions will also be answered: Does melatonin affect basal metabolic rate, increase choroidal blood flow and reduce the vasospastic syndrome (VS)? Do women with VS exhibit: a different basal metabolic rate a reduced choroidal blood flow a reduced increase of oxygen consumption after intake of ice-water a different oxygen consumption after melatonin intake a different choroidal blood flow after melatonin intake a different oxygen consumption after melatonin intake and after intake of ice-water....?

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vasospastic Syndrome
Keywords
melatonin, skin blood flow, choroidal blood flow, vasospastic subjects, normal subjects

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A, 1
Arm Type
Active Comparator
Arm Description
A, 1 = Melatonin
Arm Title
A, 2
Arm Type
Placebo Comparator
Arm Description
A,2 = Placebo
Intervention Type
Drug
Intervention Name(s)
Melatonin
Intervention Description
5mg per os
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
per os
Primary Outcome Measure Information:
Title
-choroidal blood flow -oxygen consumption -Co2 production -skin temperatures -rectal temperatures -blood pressure -eye tension
Time Frame
continously or 2-5 times

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: vasospastic syndrome healthy Exclusion Criteria: sick BMI >25 or <18 migraine drug intake
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Selim Orguel, MD
Organizational Affiliation
University Eye Clinic, Basel, Switzerland
Official's Role
Study Director
Facility Information:
Facility Name
University Eye Clinic
City
Basel
ZIP/Postal Code
4031
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow

We'll reach out to this number within 24 hrs